What Cube Dx GMBH does

Cube Dx GmbH is an Austrian molecular diagnostics company headquartered in Sankt Valentin, Austria, founded in 2015 by Christoph Reschreiter (CEO) and Bernhard Ronacher (CSO). The company develops and manufactures multiplex in-vitro diagnostic tests for severe infectious disease, with a primary focus on sepsis pathogen identification directly from whole blood. Its core technology is the hybcell — described as the world's first cylindrical microarray, where DNA oligonucleotides are immobilized on a coated cylindrical surface that rotates through samples during hybridization, intended to improve reproducibility and reduce reaction times. This is paired with the hyborg, a fully automated benchtop instrument that processes hybcell assays without user intervention and includes integrated control and analysis software. The combined 'compact sequencing' workflow links pan-bacterial (16S) and pan-fungal (28S) screening PCR with hybcell-based identification, plus sample preparation kits GINA (whole blood, up to 98% microbial DNA yield) and LINA (extraction-free modulation buffer for BAL and positive blood cultures).

The product portfolio includes CE-IVD certified and IVDR-compliant assays such as the Pathogens xB and Pathogens xC PCR kits for sepsis (covering up to 87 microorganisms and resistance genes in approximately 3 hours from 0.5 mL whole blood), the FungiPlus research-use panel (66 fungal targets), and a SARS-CoV-2 spike mutation screening assay. Cube Dx monetizes through sale of test kits/consumables (pathogen panels, GINA, LINA), instruments (hyborg Dx RED2), and reagents, reporting distributable clinical sensitivity of 74% and specificity of 98% at a limit of detection of 20 CFU/mL. The company has validated its PCR protocols on third-party thermocyclers (Biorad CFX96, Thermo Fisher QuantStudio 3/5) and sample prep instruments (PSS geneLEAD VIII, PSS MagDEA Dx SV).

Go-to-market is exclusively indirect via a network of 8 regional distributors covering 20 countries across Europe plus Jordan (Axon Lab for DACH/Benelux/CEE, Montebello for Nordics, Eurobio Scientific for France, Eurobio DID for Italy, Durviz for Spain, helix2 for Greece, Imogena for Poland, and Al Raseel Supplies for Jordan). Marketing activities are limited to a company blog, LinkedIn presence, and newsletter signup. R&D was supported by H2020 (EU) and FFG (Austria) grants and the company won first place in the Houskappreis 2023 (R&D in SMEs) for compact sequencing, receiving €150,000 of prize money. In 2024 Cube Dx completed its first crowdinvesting campaign on the ROCKETS platform, attracting more than 200 investors to fund European expansion and US market entry preparation. The CEO has publicly stated a near-term revenue target of exceeding €1 million for the first time.

Name

Cube Dx GMBH

Legal name

Cube Dx GmbH

Website

https://cubedx.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Cube Dx GmbH is an Austrian molecular diagnostics company that develops multiplex in-vitro diagnostic tests for severe infectious diseases — primarily sepsis, pneumonia, and bloodstream infections — using a proprietary cylindrical microarray platform (hybcell) and automated processing instrument (hyborg) sold through European distributors to clinical microbiology laboratories.

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Molecular diagnostics
• In-vitro diagnostics
• Clinical microbiology
• Sepsis diagnostics
• Infectious disease testing

Headquarters

HQ city

Sankt Valentin

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Molecular Diagnostic Tests and Instruments: Cube Dx develops, manufactures, and distributes multiplex diagnostic tests and automated instruments for clinical microbiology. Revenue comes from sale of test kits (PCR-boxes, hybcells), instruments (hyborg), and sample preparation reagents (GINA, LINA).
2. Test Kits and Consumables: Products include Pathogens xB, Pathogens xC test kits, hyborg Dx RED2 instruments, and various buffers and reagents for molecular diagnostics.

Go-to-market motion1 record

Distribution channels8 records

Marketing channels3 records

Core offering

Cube Dx GmbH develops, manufactures, and distributes multiplex molecular diagnostic tests and automated instruments for early detection of severe infections (sepsis, pneumonia, positive blood cultures). Its offering is built on a proprietary cylindrical microarray (hybcell), an automated processing instrument (hyborg), and a compact sequencing workflow that screens 100+ bacterial, fungal, and resistance gene targets in approximately 3 hours from whole blood. Supporting products include sample preparation kits (GINA, LINA) and PCR kits (Pathogens xB/xC) sold to clinical laboratories.

Product overview

Cube Dx GMBH is a molecular diagnostics company offering a unified platform centered on two core products: the hybcell (world's first cylindrical microarray) and hyborg (automated processing instrument). The workflow relies on compact sequencing technology combining pan-bacterial/pan-fungal PCR screening with hybcell cartridge-based identification. Supporting products include GINA (whole blood sample preparation) and LINA (extraction-free modulation buffer) kits, along with specialized PCR kits (Pathogens xB/xC) and FungiPlus. The company also offers SARS-CoV-2 mutation testing. The platform enables detection of up to 100 microbial species and resistance genes directly from blood samples in approximately 3 hours, compared to traditional culture methods requiring 2+ days.

Differentiator

Problem solved

Functional benefit

Brands

• hybcell: The world's first cylindrical microarray - DNA oligos immobilized on a cylindrical coated surface for pathogen identification
• hyborg
• compact sequencing
• GINA
• LINA

Products and services

• hybcell World's first cylindrical microarray where DNA oligos are immobilized on a coated cylindrical surface. Complementary DNA fragments in samples hybridize with probes, and fluorescence markers make binding visible. The cylindrical design rotates through samples during hybridization for improved reproducibility and reduced reaction times, used by clinical microbiology laboratories for pathogen identification.
• hyborg Fully automated instrument that processes hybcell assays, designed for use in clinical routine laboratories. Provides simple handling and clear reports with automated data analysis and electronic documentation.
• compact sequencing Two-step molecular workflow combining pan-bacterial (16S) and pan-fungal (28S) PCR screening with hybcell cartridge-based identification, enabling detection of approximately 100 bacteria, fungi and resistance genes in a single test with results in approximately 3 hours from whole blood.
• GINA Sample preparation kit for pathogen detection from whole blood. Removes human DNA and enriches microbial DNA for downstream PCR and hybcell analysis, used for sepsis diagnostics from 0.5 mL EDTA whole blood samples.
• LINA Transfer and modulation buffer enabling direct pathogen detection without DNA extraction, used for BAL samples and positive blood cultures and reducing hands-on time to approximately one minute.
• Pathogens xB Comprehensive PCR kit for sepsis diagnostics detecting up to 87 microorganisms and resistance genes from whole blood, including pan-bacterial PCR, pan-fungal PCR, and resistance gene screening. Validated for 0.5 mL EDTA blood samples with results in approximately 3 hours.
• Pathogens xC PCR kit for sepsis diagnostics with enhanced panel coverage, used together with GINA or LINA sample preparation for pathogen identification from various sample matrices.
• FungiPlus Broad molecular fungal identification test for research use detecting 16 fungal genera and 50 fungal species (66 targets total) in approximately 2.5 hours across various sample matrices including blood, BAL, urine, CSF, tissue, skin, nails, and hair.
• CuPCR SARS-CoV-2 Mutations RT-PCR test for SARS-CoV-2 mutation analysis based on TaqMan-PCR principles, combined with a hybcell SARS-CoV-2 Mutations assay for epidemiological surveillance, screening 88 SNPs in the S-gene receptor binding domain in under 2 hours total. Marketed for research and epidemiological use only.
• hyborg Dx RED2 Specific hyborg instrument model with IVDR declaration of conformity, an automated processing and reporting device for hybcell-based diagnostic assays.

Quantifiable outcome

• Time to result: 3 hours (vs 48+ hours for traditional culture)
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• T2 Biosystems: Direct competitor in rapid molecular sepsis diagnostics from whole blood. T2's T2Bacteria and T2Candida panels target the same clinical microbiology lab customer with culture-independent pathogen ID, making it the closest functional comparator to Cube Dx's compact sequencing workflow.
• Accelerate Diagnostics: Focused on rapid identification and antimicrobial susceptibility testing directly from positive blood cultures and other samples. Targets the same clinical microbiology customer with culture-to-result acceleration, overlapping with Cube Dx's positive blood culture use case.
• Curetis / OpGen: Earlier-stage molecular microbiology company developing rapid molecular panels for severe infections including sepsis and pneumonia. Closely matches Cube Dx's positioning as a smaller specialist competing against IVD majors with focused infectious disease panels.
• Mobidiag (Hologic): Developed the Amplidiag and Novodiag cartridge-based molecular diagnostic platforms for infectious disease and antibiotic resistance; acquired by Hologic. Comparable as a European-origin molecular infectious disease diagnostics platform that scaled into a strategic exit.
• GenMark Diagnostics (Roche): Developed the ePlex sample-to-answer molecular diagnostic system for syndromic infectious disease testing; acquired by Roche. Closely mirrors Cube Dx's positioning of an automated cartridge-based molecular platform for clinical microbiology labs.

Broad incumbents

• bioMérieux: Global IVD incumbent with broad microbiology offerings including the BioFire FilmArray syndromic panels for bloodstream infections and pneumonia. Competes with Cube Dx for the same clinical microbiology lab budget, but with much broader menus and global reach.
• Cepheid (Danaher): Market leader in cartridge-based molecular diagnostics (GeneXpert) with installed base in hospital clinical labs worldwide. Competes on rapid infectious disease ID with similar workflow positioning to the hyborg/hybcell platform.
• Qiagen: Major molecular diagnostics and sample preparation player with QIAstat-Dx syndromic panels and broad microbiology offerings. Overlaps with Cube Dx in molecular workflow and sample prep (analogous to GINA/LINA) for infectious disease testing.
• Bruker Microbiology: Provider of MALDI-TOF mass spectrometry (MBT) and molecular microbiology solutions for clinical labs. Competes in clinical microbiology workflow with rapid pathogen ID, including from positive blood cultures, where Cube Dx's compact sequencing also plays.
• Roche Diagnostics: Global IVD leader with broad infectious disease and microbiology portfolio including the cobas Liat and LightCycler systems. Sets the competitive benchmark for hospital molecular microbiology workflows that Cube Dx is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cube-dx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cube Dx GMBH